Table 3.
Treatment results by randomization arm
| Arm ASP-5000 | Arm ASP-10000 | p | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Total patients | 334 | 100 | 354 | 100 | |
| All relapses | 58 | 17.4 | 63 | 17.8 | 0.961 |
| Site | |||||
| Bone marrow | 37 | 11.1 | 33 | 9.3 | 0.525 |
| CNS | 5 | 1.5 | 10 | 2.8 | 0.352 |
| Testis | 1 | 0.3 | 4 | 1.1 | 0.405 |
| BM + CNS | 12 | 3.6 | 12 | 3.4 | 0.950 |
| BM + testis | 3 | 0.9 | 4 | 1.1 | 0.938 |
| Other | 0 | 0.0 | 0 | 0.0 | – |
| Secondary malignancy | 2 | 0.6 | 2 | 0.6 | 0.658 |
| Death in CR | 9 | 2.7 | 23 | 6.5 | 0.029 |
| LFU | 5 | 1.5 | 9 | 2.5 | 0.389 |
| Continuous CR | 260 | 77.8 | 257 | 72.6 | 0.115 |
ASP asparaginase, BM bone marrow, CNS central nervous system, CR complete remission, IM intramuscular, LFU lost to follow-up